Barriers to and facilitators of cancer prevention services for transgender and gender-diverse people: A systematic review.
메타분석
3/5 보강
TL;DR
Findings show that TGD people continue to experience exclusion within cancer prevention services, and addressing these disparities requires coordinated action across individual, interpersonal, system and societal levels.
OpenAlex 토픽 ·
LGBTQ Health, Identity, and Policy
Global Cancer Incidence and Screening
Cancer survivorship and care
Findings show that TGD people continue to experience exclusion within cancer prevention services, and addressing these disparities requires coordinated action across individual, interpersonal, system
APA
Deborah Jael Herrera, Lindy Huber, et al. (2026). Barriers to and facilitators of cancer prevention services for transgender and gender-diverse people: A systematic review.. Preventive medicine, 206, 108544. https://doi.org/10.1016/j.ypmed.2026.108544
MLA
Deborah Jael Herrera, et al.. "Barriers to and facilitators of cancer prevention services for transgender and gender-diverse people: A systematic review.." Preventive medicine, vol. 206, 2026, pp. 108544.
PMID
41730438 ↗
Abstract 한글 요약
[OBJECTIVE] Despite the increasing adoption of gender-inclusive policies, transgender and gender-diverse (TGD) people continue to face significant barriers to cancer prevention services, resulting in low uptake of cancer screening and HPV vaccination. This review aimed to synthesize evidence on barriers and facilitators to cancer prevention among TGD people to inform more inclusive and effective policies and programmes.
[METHODS] Searches were performed in Medline (1946), Cochrane CENTRAL (1992), CINAHL (1982), PsycINFO (1806), Web of Science (1975), and EMBASE (1971) from inception up to July 18, 2025. Thematic synthesis was guided by SURE framework, and McLeroy's socioecological model of health behaviour, adapted to cancer prevention context.
[RESULTS] A total of 1648 records were retrieved; 119 full texts were assessed and 53 studies (55 reports) met inclusion criteria. Most studies addressed cervical cancer and HPV-related prevention. Barriers were identified at individual (knowledge gaps, gender dysphoria, financial precarity), interpersonal (misgendering, discrimination, inadequate communication), healthcare-system (gendered services, insurance mismatches, lack of provider training), and societal levels (gendered messaging, stigma). Facilitators across the same levels included informed provider recommendations, affirming care environments and self-administered screening.
[CONCLUSIONS] Findings show that TGD people continue to experience exclusion within cancer prevention services. Addressing these disparities requires coordinated action across individual, interpersonal, system and societal levels.
[METHODS] Searches were performed in Medline (1946), Cochrane CENTRAL (1992), CINAHL (1982), PsycINFO (1806), Web of Science (1975), and EMBASE (1971) from inception up to July 18, 2025. Thematic synthesis was guided by SURE framework, and McLeroy's socioecological model of health behaviour, adapted to cancer prevention context.
[RESULTS] A total of 1648 records were retrieved; 119 full texts were assessed and 53 studies (55 reports) met inclusion criteria. Most studies addressed cervical cancer and HPV-related prevention. Barriers were identified at individual (knowledge gaps, gender dysphoria, financial precarity), interpersonal (misgendering, discrimination, inadequate communication), healthcare-system (gendered services, insurance mismatches, lack of provider training), and societal levels (gendered messaging, stigma). Facilitators across the same levels included informed provider recommendations, affirming care environments and self-administered screening.
[CONCLUSIONS] Findings show that TGD people continue to experience exclusion within cancer prevention services. Addressing these disparities requires coordinated action across individual, interpersonal, system and societal levels.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.